We are analyzing https://link.springer.com/article/10.1007/s00280-010-1544-1.

Title:
Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors | Cancer Chemotherapy and Pharmacology
Description:
Conatumumab is a fully human monoclonal agonist antibody against human death receptor 5 (DR5). The primary objectives of this phase 1 study were to assess the safety, tolerability, and pharmacokinetics (PK) of conatumumab in Japanese patients with advanced solid tumors. This is an open-label ascending dose study with a starting dose level of 3 mg/kg. Subsequent doses of 10 and 20 mg/kg were planned. Six patients were enrolled into 1 of 3 dose cohorts (3, 10, or 20 mg/kg) of conatumumab administered intravenously once every 2 weeks as a single agent. No conatumumab was administered on day 43 to allow the assessment of terminal PK parameters. The primary endpoints were the incidence of dose-limiting toxicities (DLTs) and assessment of PK parameters of conatumumab. Eighteen patients received at least 1 dose of conatumumab. There were no DLTs observed as defined in the protocol. No patients had an adverse event leading to conatumumab discontinuation. Conatumumab demonstrated dose-linear kinetics. A best response of stable disease was reported in nine patients. Monocytes were found to express DR5 and showed a high degree of conatumumab receptor occupancy after treatment at all dose levels. Conatumumab administered up to 20 mg/kg once every 2 weeks was well tolerated in Japanese patients with advanced solid tumors. Adverse events and PK in these patients were similar to those in the first in human (FIH) study.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Non-Profit & Charity

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

article, google, scholar, cas, pubmed, patients, cancer, antibody, phase, study, conatumumab, advanced, receptor, tumors, human, solid, death, monoclonal, agonist, dose, access, apoptosis, ligand, tumor, nat, pancreatic, cell, trail, activity, privacy, cookies, content, japanese, fully, necrosis, meeting, abstracts, apoptosisinducing, japan, publish, search, doi, mgkg, pharmacokinetic, therapy, ashkenazi, gemcitabine, asco, clin, factorrelated,

Topics {✒️}

tumor-necrosis factor superfamily pitti rm anti-her3 monoclonal antibody month download article/chapter trail-mediated cell death monocyte-mediated tumoricidal activity advanced solid tumors anti-tumor activity related subjects therapy anti-tumor effect article cancer chemotherapy pancreatic cancer cells full article pdf pancreatic cancer model privacy choices/manage cookies evaluate receptor occupancy defective thymocyte apoptosis conatumumab receptor occupancy antibody pharmacokinetics trail-induced apoptosis trail apoptotic pathway advanced tumors starting dose level dose-limiting toxicities biologic correlative study death receptor 5 gemcitabine induce apoptosis phase ia trial targeting death receptors check access instant access cancer drug discovery european economic area scope submit manuscript synergistic cytotoxic effect wiley sr accelerated autoimmune diseases asco meeting abstracts conditions privacy policy apo-2 ligand adverse event leading human monocytes stimulated newcastle disease virus immune signaling networks tnf family phase 1 study agonist activity tumoricidal activity conatumumab administered intravenously

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors
         description:Conatumumab is a fully human monoclonal agonist antibody against human death receptor 5 (DR5). The primary objectives of this phase 1 study were to assess the safety, tolerability, and pharmacokinetics (PK) of conatumumab in Japanese patients with advanced solid tumors. This is an open-label ascending dose study with a starting dose level of 3 mg/kg. Subsequent doses of 10 and 20 mg/kg were planned. Six patients were enrolled into 1 of 3 dose cohorts (3, 10, or 20 mg/kg) of conatumumab administered intravenously once every 2 weeks as a single agent. No conatumumab was administered on day 43 to allow the assessment of terminal PK parameters. The primary endpoints were the incidence of dose-limiting toxicities (DLTs) and assessment of PK parameters of conatumumab. Eighteen patients received at least 1 dose of conatumumab. There were no DLTs observed as defined in the protocol. No patients had an adverse event leading to conatumumab discontinuation. Conatumumab demonstrated dose-linear kinetics. A best response of stable disease was reported in nine patients. Monocytes were found to express DR5 and showed a high degree of conatumumab receptor occupancy after treatment at all dose levels. Conatumumab administered up to 20 mg/kg once every 2 weeks was well tolerated in Japanese patients with advanced solid tumors. Adverse events and PK in these patients were similar to those in the first in human (FIH) study.
         datePublished:2010-12-16T00:00:00Z
         dateModified:2010-12-16T00:00:00Z
         pageStart:733
         pageEnd:741
         sameAs:https://doi.org/10.1007/s00280-010-1544-1
         keywords:
            Conatumumab
            Advanced solid tumors
            Pharmacokinetics
            Phase 1 study
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-010-1544-1/MediaObjects/280_2010_1544_Fig1_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:68
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:T. Doi
               affiliation:
                     name:National Cancer Center Hospital East
                     address:
                        name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:H. Murakami
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Shizuoka Cancer Center, Nagaizumi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Ohtsu
               affiliation:
                     name:National Cancer Center Hospital East
                     address:
                        name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:N. Fuse
               affiliation:
                     name:National Cancer Center Hospital East
                     address:
                        name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:T. Yoshino
               affiliation:
                     name:National Cancer Center Hospital East
                     address:
                        name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:N. Yamamoto
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Shizuoka Cancer Center, Nagaizumi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:N. Boku
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Shizuoka Cancer Center, Nagaizumi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Y. Onozawa
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Shizuoka Cancer Center, Nagaizumi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C-P. Hsu
               affiliation:
                     name:Amgen Inc.
                     address:
                        name:Amgen Inc., Thousand Oaks, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:K. S. Gorski
               affiliation:
                     name:Amgen Inc.
                     address:
                        name:Amgen Inc., Thousand Oaks, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:G. Friberg
               affiliation:
                     name:Amgen Inc.
                     address:
                        name:Amgen Inc., Thousand Oaks, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:T. Kawaguchi
               affiliation:
                     name:Takeda Bio Development Center Ltd.
                     address:
                        name:Takeda Bio Development Center Ltd., Tokyo, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:T. Sasaki
               affiliation:
                     name:Takeda Bio Development Center Ltd.
                     address:
                        name:Takeda Bio Development Center Ltd., Tokyo, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors
      description:Conatumumab is a fully human monoclonal agonist antibody against human death receptor 5 (DR5). The primary objectives of this phase 1 study were to assess the safety, tolerability, and pharmacokinetics (PK) of conatumumab in Japanese patients with advanced solid tumors. This is an open-label ascending dose study with a starting dose level of 3 mg/kg. Subsequent doses of 10 and 20 mg/kg were planned. Six patients were enrolled into 1 of 3 dose cohorts (3, 10, or 20 mg/kg) of conatumumab administered intravenously once every 2 weeks as a single agent. No conatumumab was administered on day 43 to allow the assessment of terminal PK parameters. The primary endpoints were the incidence of dose-limiting toxicities (DLTs) and assessment of PK parameters of conatumumab. Eighteen patients received at least 1 dose of conatumumab. There were no DLTs observed as defined in the protocol. No patients had an adverse event leading to conatumumab discontinuation. Conatumumab demonstrated dose-linear kinetics. A best response of stable disease was reported in nine patients. Monocytes were found to express DR5 and showed a high degree of conatumumab receptor occupancy after treatment at all dose levels. Conatumumab administered up to 20 mg/kg once every 2 weeks was well tolerated in Japanese patients with advanced solid tumors. Adverse events and PK in these patients were similar to those in the first in human (FIH) study.
      datePublished:2010-12-16T00:00:00Z
      dateModified:2010-12-16T00:00:00Z
      pageStart:733
      pageEnd:741
      sameAs:https://doi.org/10.1007/s00280-010-1544-1
      keywords:
         Conatumumab
         Advanced solid tumors
         Pharmacokinetics
         Phase 1 study
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-010-1544-1/MediaObjects/280_2010_1544_Fig1_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:68
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:T. Doi
            affiliation:
                  name:National Cancer Center Hospital East
                  address:
                     name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:H. Murakami
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Shizuoka Cancer Center, Nagaizumi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Ohtsu
            affiliation:
                  name:National Cancer Center Hospital East
                  address:
                     name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:N. Fuse
            affiliation:
                  name:National Cancer Center Hospital East
                  address:
                     name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:T. Yoshino
            affiliation:
                  name:National Cancer Center Hospital East
                  address:
                     name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:N. Yamamoto
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Shizuoka Cancer Center, Nagaizumi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:N. Boku
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Shizuoka Cancer Center, Nagaizumi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Y. Onozawa
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Shizuoka Cancer Center, Nagaizumi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C-P. Hsu
            affiliation:
                  name:Amgen Inc.
                  address:
                     name:Amgen Inc., Thousand Oaks, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:K. S. Gorski
            affiliation:
                  name:Amgen Inc.
                  address:
                     name:Amgen Inc., Thousand Oaks, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:G. Friberg
            affiliation:
                  name:Amgen Inc.
                  address:
                     name:Amgen Inc., Thousand Oaks, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:T. Kawaguchi
            affiliation:
                  name:Takeda Bio Development Center Ltd.
                  address:
                     name:Takeda Bio Development Center Ltd., Tokyo, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:T. Sasaki
            affiliation:
                  name:Takeda Bio Development Center Ltd.
                  address:
                     name:Takeda Bio Development Center Ltd., Tokyo, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:68
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:National Cancer Center Hospital East
      address:
         name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Shizuoka Cancer Center, Nagaizumi, Japan
         type:PostalAddress
      name:National Cancer Center Hospital East
      address:
         name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
         type:PostalAddress
      name:National Cancer Center Hospital East
      address:
         name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
         type:PostalAddress
      name:National Cancer Center Hospital East
      address:
         name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Shizuoka Cancer Center, Nagaizumi, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Shizuoka Cancer Center, Nagaizumi, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Shizuoka Cancer Center, Nagaizumi, Japan
         type:PostalAddress
      name:Amgen Inc.
      address:
         name:Amgen Inc., Thousand Oaks, USA
         type:PostalAddress
      name:Amgen Inc.
      address:
         name:Amgen Inc., Thousand Oaks, USA
         type:PostalAddress
      name:Amgen Inc.
      address:
         name:Amgen Inc., Thousand Oaks, USA
         type:PostalAddress
      name:Takeda Bio Development Center Ltd.
      address:
         name:Takeda Bio Development Center Ltd., Tokyo, Japan
         type:PostalAddress
      name:Takeda Bio Development Center Ltd.
      address:
         name:Takeda Bio Development Center Ltd., Tokyo, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:T. Doi
      affiliation:
            name:National Cancer Center Hospital East
            address:
               name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:H. Murakami
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Shizuoka Cancer Center, Nagaizumi, Japan
               type:PostalAddress
            type:Organization
      name:A. Ohtsu
      affiliation:
            name:National Cancer Center Hospital East
            address:
               name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
               type:PostalAddress
            type:Organization
      name:N. Fuse
      affiliation:
            name:National Cancer Center Hospital East
            address:
               name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
               type:PostalAddress
            type:Organization
      name:T. Yoshino
      affiliation:
            name:National Cancer Center Hospital East
            address:
               name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
               type:PostalAddress
            type:Organization
      name:N. Yamamoto
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Shizuoka Cancer Center, Nagaizumi, Japan
               type:PostalAddress
            type:Organization
      name:N. Boku
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Shizuoka Cancer Center, Nagaizumi, Japan
               type:PostalAddress
            type:Organization
      name:Y. Onozawa
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Shizuoka Cancer Center, Nagaizumi, Japan
               type:PostalAddress
            type:Organization
      name:C-P. Hsu
      affiliation:
            name:Amgen Inc.
            address:
               name:Amgen Inc., Thousand Oaks, USA
               type:PostalAddress
            type:Organization
      name:K. S. Gorski
      affiliation:
            name:Amgen Inc.
            address:
               name:Amgen Inc., Thousand Oaks, USA
               type:PostalAddress
            type:Organization
      name:G. Friberg
      affiliation:
            name:Amgen Inc.
            address:
               name:Amgen Inc., Thousand Oaks, USA
               type:PostalAddress
            type:Organization
      name:T. Kawaguchi
      affiliation:
            name:Takeda Bio Development Center Ltd.
            address:
               name:Takeda Bio Development Center Ltd., Tokyo, Japan
               type:PostalAddress
            type:Organization
      name:T. Sasaki
      affiliation:
            name:Takeda Bio Development Center Ltd.
            address:
               name:Takeda Bio Development Center Ltd., Tokyo, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
      name:Shizuoka Cancer Center, Nagaizumi, Japan
      name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
      name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
      name:Gastrointestinal/Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
      name:Shizuoka Cancer Center, Nagaizumi, Japan
      name:Shizuoka Cancer Center, Nagaizumi, Japan
      name:Shizuoka Cancer Center, Nagaizumi, Japan
      name:Amgen Inc., Thousand Oaks, USA
      name:Amgen Inc., Thousand Oaks, USA
      name:Amgen Inc., Thousand Oaks, USA
      name:Takeda Bio Development Center Ltd., Tokyo, Japan
      name:Takeda Bio Development Center Ltd., Tokyo, Japan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(121)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.77s.

LINK . SPRINGER . COM {}